Stocktoria
Q32 Bio Inc. QTTB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-03-28
Q32 Bio Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $53.7M | $0 | -$6.7M | $3.2M | $34.0M |
| R&D expense | $19.2M | $48.1M | $31.7M | $98.4M | $93.1M |
| Operating income | $16.9M | -$66.1M | -$48.3M | -$133.3M | -$95.9M |
| Income tax | $0 | $21,000 | $318,000 | $715,000 | $0 |
| Net income | $29.8M | -$47.7M | -$53.7M | -$5.0M | -$95.8M |
| EPS (diluted) | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 |
| Operating cash flow | -$33.5M | -$67.7M | -$18.7M | -$113.7M | -$109.8M |
| Free cash flow | -$33.5M | -$67.8M | -$18.7M | -$114.9M | -$112.1M |
| Cash & equivalents | $48.3M | $78.0M | $25.6M | $34.0M | $108.4M |
| Total assets | $61.8M | $92.3M | $47.1M | $228.5M | $211.7M |
| Total liabilities | $19.8M | $86.7M | $118.5M | $50.5M | $42.1M |
| Shareholders' equity | $42.0M | $5.7M | -$182.9M | -$130.7M | $169.7M |
Source: SEC EDGAR filings · CIK 0001661998 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.